Details of the Drug

General Information of Drug (ID: DMLCTBP)

• Drug Name: VTX-2337
• Synonyms: Motolimod; 926927-61-9; VTX-2337; Motolimod (VTX-2337); UNII-WP6PY72ZH3; VTX-378; VTX 2337; WP6PY72ZH3; AK171372; Motolimod [USAN:INN]; Motolimod (USAN/INN); SCHEMBL254984; GTPL9026; CHEMBL3301618; KS-00000SZB; DTXSID10239107; MolPort-039-136-930; EX-A1102; BCP16667; ZINC34946588; s7161; AKOS025289797; SB16930; DB12303; HY-13773; KB-146010; J3.657.311B; D10716; 2-amino-N,N-dipropyl-8-[4-(pyrrolidine-1-carbonyl)phenyl]-3H-1-benzazepine-4-carboxamide

Indication

Disease Entry	ICD 11	Status	REF
Allergy	4A80-4A85	Discontinued in Phase 2	[1]

• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 458.6
  Logarithm of the Partition Coefficient (xlogp); 3.8
  Rotatable Bond Count (rotbonds); 7
  Hydrogen Bond Donor Count (hbonddonor); 1
  Hydrogen Bond Acceptor Count (hbondacc); 3
• Chemical Identifiers:
  Formula: C28H34N4O2
  IUPAC Name: 2-amino-N,N-dipropyl-8-[4-(pyrrolidine-1-carbonyl)phenyl]-3H-1-benzazepine-4-carboxamide
  Canonical SMILES: CCCN(CCC)C(=O)C1=CC2=C(C=C(C=C2)C3=CC=C(C=C3)C(=O)N4CCCC4)N=C(C1)N
  InChI: InChI=1S/C28H34N4O2/c1-3-13-31(14-4-2)28(34)24-17-23-12-11-22(18-25(23)30-26(29)19-24)20-7-9-21(10-8-20)27(33)32-15-5-6-16-32/h7-12,17-18H,3-6,13-16,19H2,1-2H3,(H2,29,30)
  InChIKey: QSPOQCXMGPDIHI-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 16049404
  CAS Number: 926927-61-9
  DrugBank ID: DB12303
  TTD ID: D0H3JF

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Toll-like receptor 8 (TLR8)	TT8CWFK	TLR8_HUMAN	Modulator	[2]

References

• [1] ClinicalTrials.gov (NCT01666444) VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer. U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of Array BioPharma (Drug: Motolimod / VTX2337).